HCW Biologics is trading 6.8% down at $1.38 in pre-market on October 13, 2026, versus the provided previous close of $1.48; the catalyst remains unconfirmed. - No company-specific announcement explaining the October 13 move was identified; broader market context is mixed. - The October 9 update reported progress toward an IND application for its lead T-cell engager. - An October 2 registration statement covers resale of up to 1,807,228 shares by a selling stockholder; it is a potential overhang, but causation is unconfirmed.